Evidence map›Paper›PMID 39924245›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Concurrent Therapy for Immunoglobulin Light Chain Cardiac Amyloidosis and Transthyretin Cardiac Amyloidosis.

Yuichi Horigome, Shunsuke Ishii, Manabu Matsumoto, Yoshihiko Ikeda, Kinta Hatakeyama, Junya Ako, Takahiro Suzuki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuichi HorigomeDepartment of Hematology, Kitasato University School of Medicine, Japan.
Shunsuke IshiiDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Japan.
Manabu MatsumotoDepartment of Pathology, National Cerebral and Cardiovascular Center, Japan.
Yoshihiko IkedaDepartment of Pathology, National Cerebral and Cardiovascular Center, Japan.
Kinta HatakeyamaDepartment of Pathology, National Cerebral and Cardiovascular Center, Japan.
Junya AkoDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Japan.
Takahiro SuzukiDepartment of Hematology, Kitasato University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac amyloidosis (CA), predominantly caused by amyloid transthyretin (ATTR) or immunoglobulin light chain (AL), has a poor prognosis, and a precise diagnosis is crucial because the optimal treatments differ between the two conditions. However, diagnosing AL-CA is challenging because of the unavailability of effective AL-detecting antibodies, particularly in cases with coexisting AL- and ATTR-CA. This report presents a successfully diagnosed case of complicated AL- and ATTR-CA that was successfully treated with tafamidis for ATTR-CA and combination chemotherapy for AL-CA. This case highlights the importance of a precise diagnosis of CA and supports the efficacy and safety of concurrent treatment for coexisting amyloidosis.

Indexed as

Amyloid Neuropathies, FamilialBenzoxazolesCardiomyopathiesImmunoglobulin Light-chain AmyloidosisImmunoglobulin Light ChainsDrug Therapy, CombinationHumansTreatment OutcomeBenzoxazolesImmunoglobulin Light ChainstafamidisAL-amyloidosisATTR-amyloidosisdaratumumabsafetytafamidis

Identifiers

PMID39924245
PMCPMC12425582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.